# EMA CHMP Recommends Label Update to Novo Nordisk’s Wegovy ## Key Points: – The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to the label of Novo Nordisk’s Wegovy. – Wegovy, also known as semaglutide 2.4 mg, is a once-weekly injection for chronic weight management in adults with obesity. – The label update follows positive results from the STEP and SELECT clinical trials, demonstrating the efficacy and safety of Wegovy in helping patients achieve significant weight loss. – The updated label will reflect the benefits of using Wegovy as an adjunct to diet and exercise for weight management. ## Hot Take: The EMA CHMP’s recommendation for a label update to Novo Nordisk’s Wegovy highlights the continued progress in the field of weight management pharmaceuticals. This positive development showcases the growing options available for individuals looking to achieve sustainable weight loss. Contact Mindful Evolution today to explore how telehealth services can support your weight loss journey in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Weight Loss Disclaimer: Individual results may vary. Consult with a healthcare provider before starting any weight loss program.